<DOC>
	<DOC>NCT00670449</DOC>
	<brief_summary>This study was an extension study of NCT00537082. This study was designed to evaluate the efficacy and safety of long-term administration of 0.5 mg or 1.25 mg of fingolimod (FTY720) to relapsing multiple sclerosis.</brief_summary>
	<brief_title>An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description>A decision was made to switch all patients on fingolimod 1.25 mg/day to fingolimod 0.5 mg/day in an amendment to the study protocol. The study became open-label with all patients receiving fingolimod 0.5 mg/day on 22 Feb 2010. The efficacy data for Months 0-6 in this study report is from the core study NCT00537082.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Patients who completed 6 months of treatment with the study drug and the Month 6 visit in the core study NCT00537082. Females of childbearing potential who have a negative pregnancy test in the core study NCT00537082. Patients who permanently discontinued study drug treatment prior to the Month 6 visit in the core study NCT00537082. Other protocoldefined inclusion/exclusion criteria applied to the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>FTY720</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>MS</keyword>
</DOC>